Clinical trial · Interventional
Lymph Node Ratio and Kras Mutation in R Colon Cancer
Lymph Node Ratio and Kras Mutation in Risk Stratification of Colon Cancer
NCT04342676CI-TRIAL-00044620completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
clinical impact of LN ratio with Kras expression in colon cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer Stage III | Malignant Colon Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| k ras | Device | — | UNRESOLVED |
| Panitumumab | Drug | Panitumumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- patients
- description
- LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )
- interventionNames
- Device: k ras
- Drug: Panitumumab
Primary outcomes (1)
- measure
- LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).
- timeFrame
- 2 years
- description
- impact on response
Secondary outcomes (1)
- measure
- LNR and K ras were evaluated and ASSOCIATION with PFS and OS.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Stage III colon cancer Exclusion Criteria: * Stage I, II, IV
References
Publications (0)
Data not yet available
No reference posted for this study.